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Decrease of prostaglandin 12 binding sites in thyroid cancer
I. Virgolinil, M. Hermann2 & H. Sinzingerl
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Summary The properties of specific prostaglandin 12 (prostacyclin, PG12) binding sites in normal thyroid
tissue have been characterised. Tissue samples obtained intraoperatively from patients with 'cold' solitary
thyroid nodules (as preoperatively selected by thyroid gland scintigraphy, thyroid gland ultrasonography and
Papanicolaou cytology following fine needle aspiration of the nodule area) have been used for thyroid
membrane preparation. Employing [3H]iloprost, a chemically stable PG12-analogue as a radioligand,
saturation experiments for comparative binding studies have been attempted. Scatchard analysis of the
binding data obtained for normal thyroid parenchyma distant to the nodule area revealed heterogeneity of the
[3H]iloprost sites exhibiting a high-affinity binding capacity (Bmax) of 613.2+130.4fmolmg-1 membrane
protein and a low-affinity binding capacity of 5.1+1.6pmolmg- 1 membrane protein. The equilibrium
dissociation constant (Kd) amounted to 18.9+8.9nM and to 131.5+39.2nM, respectively. Scatchard analysis
of the binding data obtained for benign thyroid adenoma indicated significant lower binding capacities
exhibiting a Bmax of 325.8 + 110.0fmolmg- 1 membrane protein (Kd: 31.0+7.5nM) for the high-affinity sites
and of 3.9 +2.5pmol mg-1 membrane protein (Kd: 364.9+ 183.6) for the low affinity sites. In cancer tissue a
selective loss of the low affinity sites and a significant diminution of the high-affinity sites was observed: in
well differentiated cancer the high-affinity sites showed a Bmax of 299.7+46.0fmolmg-1 membrane protein
(Kd: 38.9 +7.3 nM), in anaplastic cancer, less differentiated papillar and follicular cancers of
180.6 +25.1 fmol mg - membrane protein (Kd: 54.6+ 16.7nM). Well differentiated papillar and follicular
cancers did not differ from each other.
It is concluded that thyroid neoplasms have different binding capacities of PGI2-high-affinity binding sites
depending on their differentiation status. The significant loss (P<0.001) of specific binding sites for PG12 in
the cancer state could possibly give a new clue for diagnosis or treatment.
The metabolism of cAMP and prostaglandins is altered in a
great many cancers. Prostaglandins are associated with the
activation of the adenylate cyclase-cAMP-system through
specifically membrane bound receptors that have been
demonstrated in several tissue fractions or at cell surface
membranes (e.g., Hall & Strange, 1984, Riicker & Schr6r,
1983; Virgolini, 1987). Increased response to prostaglandins
by measuring the cAMP content in neoplastic tissue has
been observed in various studies (e.g., Bronsted et al., 1978;
Chayoth et al., 1973), thus prostaglandins are proposed to
take part in cellular growth (Feher & Gridali, 1974; Hial et
al., 1976). For thyroid cancer the effects of prostaglandins
and of their synthesis inhibitors aspirin or indomethacine
have been rarely reported in the literature (Sand et al., 1976),
although an alteration in adenylate cyclase activity has been
indicated in thyroid cancers (De Rubertis et al., 1972;
Orgiazzi et al., 1977).
The present study investigated the binding of prosta-
glandin 12 (PGI2, Moncada et al., 1976) to solitary 'cold'
nodules. Normal thyroid tissue was compared with benign
thyroid adenomas, well differentiated and less differentiated
cancers. Iloprost, (ZK36374, Skuballa & Vorbriiggen, 1983),
a chemically stable derivative of PGI2, in soluble form,
offered the unique possibility for obtaining reproducible
results.
Materials and methods
Patients and clinical data
Sixteen patients with solitary palpable thyroid nodules which
did not concentrate 1 mCi 99m Tc (Dept. of Chemistry,
SGAE Seibersdorf, Austria) after 10,IU TSH-treatment
(Henning, Berlin, FRG) were classified as 'cold nodule
bearers' and selected for the receptor study. The patients
were males (n=4) and females (n=12) aging from 39 to 81
years. By the time of surgery all the patients had normal
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peripheral hormone levels as measured by routine radio-
immunoassays for the free T4 (Riagnost FT4, Behringwerke
AG, Marburg, FRG), free T3 (Coat-A-Count Free T3,
Diagnostic Products Corporation, Los Angeles, Ca, USA),
and TSH (Riagnost hTSH, Behringwerke AG, Marburg,
FRG) before and 30min after 0.2mg TRH-application
(Henning, Berlin, FRG). None of the patients received anti-
thyroid medication within 1 month before surgery. Patients
suffering from any other endocrinological disorder were
excluded from the study. Fine needle aspirations of the
nodule area were stained according to Papanicolaou. Ultra-
sonography was employed to differentiate the cytic lesions
from the mixed or solid lesions, only patients with the latter
were selected.
Each patient undergoing surgery for those suspicious
nodules in thyroid gland scintigraphy and thyroid fine needle
aspiration received the same anaesthetic. At surgery, 1 g
(wet weight) of the excised 'cold' nodule tissue was immedia-
tely cooled to 4°C and transported to the laboratory.
Intraoperatively one sample was taken for histological classi-
fication (H&E staining). Normal thyroid tissue was obtained
from the resting parenchyma distant to the nodule area.
Histological diagnosis, Papanicolaou stain and clinical stag-
ing according to the TNM-system are listed in Table I.
The histologically verified fresh thyroid tissue was used for
the receptor study within half an hour of removal.
Preparation of human thyroid membrane fraction
About 1 g (wet weight) thyroid tissue (normofollicular, aden-
oma or cancer tissue) was used for the membrane prep-
aration. The method used was a modification described and
verified previously (Kowalsky et al., 1972; Moore & Wolff,
1973). The tissue slice obtained was cut into small pieces and
carefully separated from connective tissue using surgical
blades (Aesculap-Werke AG, Tuttlingen, FRG). The pieces
were then washed in assay buffer containing 50mM Tris-
HCl-buffer (pH 7.8) and 5 mM MgCl2 and centrifuged at
500g for 10min at 4°C (Beckman J-6B Centrifuge, Miinchen,
FRG). The pellet was suspended in 4°C buffer containing
25mM Tris-HCl (pH 7.8), 1 mM MgCl2 and 0.25 M sucrose,
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and homogenized by means of an ultraturrax (Typ 18/10,
IKA-Labortechnik, Staufen, FRG) and 20s ultrasound
(Heat Systems Ultrasonic, sonicator W 220F, New York,
USA). The whole homogenate was filtered through a fine
mesh screen to remove the remaining connective tissue and
centrifuged at 150g for 5min. The supernatant was kept on
ice and the pellet rehomogenized and again centrifuged at
150g for 5min at 4°C. The 2 supernatants were combined
and centrifuged at 4,000g for 10min at 4°C. The pellet was
washed twice in assay buffer and the resulting membrane
fraction was finally taken up in assay buffer at a protein
concentration of -50-100Mg/i00p1 membrane protein using
the assay kit provided by Bio-Rad (Commassie Brilliant Blue
G-250, Richmond, Ca, USA).
Filtration assay of [3H]iloprost binding experiments
A vacuum filtration assay was employed. The technique used
was a modification of the method described by Kuehl &
Humes (1972). For comparative studies saturation experi-
ments were performed. Each of the 22 separate experiments
consisted of 36 to 48 assay samples. Finally in the tubes a
total assay vol of 200p1 was incubated for 40min at 4°C.
These standardized assay conditions were obtained from
studies on time- and temperature-dependency (Virgolini,
1987). Reproducibility was checked by analysis of the count
rates of triplicate test tubes in the higher ligand ranges and
duplicate test tubes in the lower ligand ranges. The intra-
assay variability was 4.3+0.8% and the inter-assay variabi-
lity, 6.4+1.1%.
The thyroid membrane fraction (50-100pg per I00M1
membrane protein) was incubated in 80Ml assay buffer with
20,ul [3H]iloprost over the concentration range 2.5-160 nM
in order to determine total binding. Twenty ,ul of increasing
concentrations of [3H]iloprost were incubated in 60M1 assay
buffer in the presence of 20 l/S500, M unlabelled iloprost to
determine non-specific binding. Specific binding was deter-
mined as the difference of total binding and non-specific
binding. After incubation for 40min at 4°C the reaction-
mixture was diluted rapidly with 3ml of 4°C assay buffer
and the entire mixture immediately poured onto a Whatman
GF/B filter (Maidstone, UK), which was positioned on a
vacuum system (Millipore, Harrow, UK). The tubes were
then rinsed once with 5ml 25mM Tris-HCl-buffer and each
filter washed with two 5ml portions of 4°C Tris-HCI-buffer.
After completion of filtration and washing (for <1Os) the
filters were dried under vacuum, then transferred into scintil-
lation vials (Pachard, Downers Grove, USA) and taken up
into 10ml scintillation fluid (Pico-Fluor TM30, Packard,
Downers Grove, USA). The radioactivity in the samples was
counted for 5min in a liquid scintillation counter (LKB
Wallace, 1215 Rackbeta, Turku, Finland) at an efficiency of
45%. K. Schillinger and T. Krais (Schering AG, Berlin,
FRG) kindly provided unlabelled iloprost. [3H]iloprost was
obtained from Amersham International, Buckinghamshire,
UK (specific activity 14.8 Cimmol- 1, radiochemical purity
98.7%).
Calculations
Saturation data were subject to Scatchard analysis
(Scatchard, 1947) indicating heterogeneity of the binding
sites in normal thyroid tissue. Fitting of the experimental
data, in terms of specifically bound ligand versus total ligand
concentration to Scatchard models was performed by a
computer program (Neumann, 1988).
Values are given as x+s.d. Student's t-test was employed
for paired data.
Results
Histological diagnosis, cytological results and clinical classifi-
cation according to the TNM-system are listed in Table I.
The mean values (n= 16) of the radioimmunoassays for FT4
were 1.4+0.3ngdl- 1 (0.8-2.Ongdl-1), for FT3 to 1.8
±0.5pgml-1 (1.3-3.6pgml-1), for basal TSH to 1.4
±0.7MUml-1 (0.0-5.OMUml-1) and for TSH after TRH-
application: 8.3 +2.7 (<7-25 Uml-1). Cytological results
ranged from Papanicolau 0 to V.
Saturation of [3H]iloprost binding and Scatchard analysis
on normal thyroid (Figure 1)
Specific binding (determined as the difference of total and
non-specific binding) of [3H]iloprost to normal thyroid tissue
as a function of increasing ligand concentrations (2.5-
160nM) under standardized assay conditions (4°C, 40min
incubation time) showed the presence of 613.2 +
130.4fmolmg- membrane protein of the high affinity
binding sites (=Bmax, maximal number of binding sites)
with an apparent equilibrium dissociation constant (Kd) of
18.9 +8.9 nM. The non-linear relationship between bound/
free [3H]iloprost and bound [3H]iloprost identified a complex
system, which had been analyzed employing a computer
model fitting the data to 2 independent binding sites. The
low affinity binding sites saturated at 5.1 + 1.6pmol mg 1
Table I Clinical data of the patients
Histological Papanicolaou TNM Bmax Kd
Pat. Age Sex diagnosis staging staging (fmolmg-1protein) (nM)
JG 39 f microfollicular adenoma 0 - 461.0 37.0
HM 68 f macrofollicular adenoma 0 455.7 40.6
LG 45 f macrofollicular adenoma II 248.9 23.8
MM 67 f macrofollicular adenoma II 333.4 35.2
MR 52 f microfollicular proliferative II 217.0 29.3
ML 57 f macrofollicular proliferative adenoma II 238.7 22.0
mean value: 325.8+110.0 31.3+7.5
SE 52 f papillar cancer well differentiated III TINIMO 328.9 46.2
SF 36 m papillar cancer well differentiated IV T2NlMO 359.2 44.9
XH 69 m follicular cancer well differentiated IV TlN2MO 253.6 32.8
HH 67 f follicular cancer well differentiated V T2NlMO 255.5 40.9
LA 74 f follicular cancer well differentiated IV T2N2M0 301.2 29.9
mean value: 299.7+46.0 38.9+7.3
RS 73 f anaplastic cancer V T2N3M1 218.1 71.4
BJ 70 m anaplastic cancer V T3N3M1 176.0 59.4
DM 47 m anaplastic cancer recurrent V T2N3M1 153.2 67.9
SM 81 f papillar cancer less differentiated V T4N3M1 165.3 39.8
DB 56 f follicular cancer less differentiated V T4N3M3 190.6 34.4
mean value: 180.6+25.1 54.6+ 16.7586 I. VIRGOLINI et al.
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Figure 1 Saturation of specific [3H]iloprost binding to normal
human thyroid (e) and benign solitary adenoma (U). The
fractions (100 g protein per 100pl) have been incubated with
increasing concentrations of [3H]iloprost (2.5-150 nM) at 4°C.
Each point represents the average of 6 separate experiments.
Insert: Scatchard analysis of [3H]iloprost binding on normal
thyroid and on benign solitary adenoma at equilibrium. Specific
binding is expressed as pmol iloprost bound mg-' protein; free
iloprost is expressed as nM.
membrane protein and for this site the Kd was
131.5+39.2nM. The proportion of high affinity binding sites
relative to those of low affinity was -15-20%; the percent-
age of specific [3H]iloprost binding was -80% in the high
affinity binding range.
Saturation of [3H]iloprost binding and Scatchard analysis
on solitary benign thyroid adenoma (Figure 1)
Under the same assay conditions (4°C, 40min incubation
time) saturation of the high affinity sites could be achieved
between 30 and 60nM of the [3H]iloprost concentrations.
These binding sites showed a Bmax of 325.8+
110.Ofmolmg-' membrane protein and a Kd 31.3+
7.5nM. As in normal thyroid tissue a second binding
capacity was observed up from 60nM of the ligand added.
However, this binding was not saturable within the used
ligand concentrations (160nM) and exhibited a Kd of
364.9+183.6nM and a Bmax of 3.9+2.5pmolmg-1 mem-
brane protein. The proportion of high-affinity binding sites
relative to those of low affinity was -15%.
Saturation of [3H]iloprost binding and Scatchard analysis
on cancers of varying differentiations (Figures 2 and 3)
Specific binding of [3H]iloprost to well differentiated thyroid
cancer as a function of increasing ligand concentration (2.5-
160nM) under standardized assay conditions showed the
presence of 299.7+46.0fmolmg- I membrane protein of high
affinity binding sites with an apparent Kd of 38.9+7.3 nM.
Well differentiated papillar and follicular cancers did not
differ from each other (Table I). The decrease of high-
affinity sites in well differentiated tumour tissue was signifi-
cant (P<0.005) compared to normal thyroid tissue, but was
not significant compared to thyroid benign adenoma. In less
differentiated thyroid cancer and in anaplastic cancer the
Bmax amounted to 180.6+25.1 fmolmg - membrane protein
suggesting a diminution of .70% of [3H]iloprost high
affinity binding sites (P<0.001). In comparison to normal
thyroid tissue the Kd increased to 54.6+16.7nM (P<0.001).
The low affinity binding sites observed in normal thyroid
tissue and in thyroid benign adenoma were not demonstrable
in well and in less differentiated thyroid cancer.
Discussion
The thyroid nodule is still a controversial topic in clinical
medicine as various thyroid diseases may manifest themselves
[3HI lloprost (nM)
Figure 2 Saturation of specific [3H]iloprost binding to well
differentiated (0, n=5) and less differentiated (A, n=5) thyroid
cancer. Increasing concentrations of [3H]iloprost (2-160nM)
have been incubated with the thyroid membrane fractions (50-
100 lg protein per 100 Ml) at 4°C for 40 min. At concentrations
of > 100 nM no specific binding was observed.
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Figure 3 Scatchard analysis of specific [3H]iloprost binding at
equilibrium on well differentiated (0) and less differentiated (A)
cancer. Scatchard analysis is linear. Each point represents the
average of 5 separate determinations. Specific binding is
expressed as fmol of iloprost bound mg' protein; free iloprost
is expressed as nM.
as a thyroid nodule. 'Cold nodules' are a clinical concern
due to the risk of malignancy frequently requiring surgical
excision (Kendall & Condon, 1969; Perlmutter et al., 1954;
Van Herle et al., 1982).
The demonstration of prostaglandins in the thyroid gland
is consistent with the suggestion that they exert an important
direct role on the gland (Haye et al., 1973; Friedman et al.,
1976; Boenynaemes et al., 1980; Takasu et al., 1981). PGI2
(Kasai et al., 1986) like the prostaglandins of the E series
(Kovalsky et al., 1972; Takasu et al., 1976; Shenkman et al.,
1974) are known to stimulate intracellular thyroid processes
through interaction with specifically surface membrane-
bound receptors (Brown & Wolff, 1973; Virgolini, 1987). At
present PGI2 is considered to be an important regulator of
cell metabolism in various tissues (Moncada & Vane, 1984).
Takasu et al. (1981) first suggested that PGI2 also has an
important role in thyroid cell function. However, a major
problem in studying PGI2 is its instability in aqueous
medium at pH 7.4 because of rapid hydrolysis into the
biologically inactive degradation product of 6-oxo-PGF,,
(Moncada et al., 1976). Iloprost was found to be equivalent
to PGI2 (Skuballa & Vorbriiggen, 1983) in respect of
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anticoagulant and vasodilatory activities. Therefore, this
chemically stable derivative offered the unique possibility to
study PGI2-binding by using the radiolabelled compound as
a ligand. The technique was previously successfully used by
others to demonstrate binding sites on other tissues such as
vascular tissue (Riucker & Schr6r, 1983) or rat gastric
mucosa (Beinborn et al., 1985).
Figures 4 and 5 summarize the Bmax and Kd values
obtained for the high affinity binding sites: the Bmax value
significantly decreases from normal thyroid tissue to the less
differentiated cancer (P<0.001) and the Kd value signifi-
cantly increases from normal thyroid tissue to the less
differentiated cancer (P<0.001). Anaplastic and less differen-
tiated papillar or follicular cancers do not differ from each
other. The Kd and Bmax values obtained for the high
affinity binding sites of well differentiated cancer and benign
solitary adenoma are very similar. Scatchard analysis
revealed a high and a low affinity binding class in normal
thyroid tissue. In benign solitary adenoma the large Kd
value obtained for the low affinity binding sites apparently
reveals a loss of affinity to these sites, and in the malignant
state low affinity binding was not demonstrable at all. Since
all the binding assays were conducted under identical labora-
tory conditions it is assumed that the significant differences
are related to neoplastic transformation of the cells. It
appears that depending on the differentiation of the 'cold'
thyroid nodule the PGI2-binding capacity decreases, and this
800
@ 600-
0
l.
E
Z3 400
E
200-
O- I 11 III IV
Figure 4 Comparison of the Bmax of the high affinity sites of
normal thyroid tissue (I, n =6), benign solitary adenoma (II,
n =6), well differentiated cancer (III, n =5) and less differentiated
cancer (IV, n=5). The binding capacity significantly decreases
from normal thyroid tissue to the malignant state (P<0.001).
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Figure 5 Comparison of the Kd of the high affinity sites of
normal thyroid tissue (I, n =6), benign solitary adenoma (II,
n=6), well differentiated cancer (III, n=5) and less differentiated
cancer (IV, n=5). The Kd increases significantly from normal
thyroid tissue to less differentiated cancer (P<0.001).
'process' may onset at the low affinity sites. Recently similar
results were obtained at the PGE1-receptor level in human
hepatocellular cancer (Virgolini et al., 1988).
The degree of differentiation of a tumour ranging from
poorly to well differentiated, often provides a clue to prog-
nosis or a guide to treatment. As might be expected, the less
differentiated the tumour the more aggressive its behaviour
and the poorer the prognosis. Kerr et al. (1986) demon-
strated a significant influence of histological type, TNM
status and age on the survival rate of patients with thyroid
cancer. In the present study the decrease of the Bmax and
the increase of the Kd of the high affinity binding sites
correlate with the histological and cytological diagnosis of
the tumour and TNM classification. As hormone sensitive
cancers contain receptors, the measurement of receptor levels
in surgically removed tumours might be of prognostic and
therapeutic value. However, little is known about the effects
of the prostaglandins on thyroid gland in the malignant
state. Thus, further investigations are necessary to elucidate
the role of PGI2 during thyroid carcinogenesis.
Prof. K. Keminger (Dept. of Surgery, Elisabeth Hospital) kindly
provided the surgical material and Dr Edith Schmalzer (Dept. of
Pathology, Kaiserin-Elisabeth Hospital) the histological diagnosis.
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